Objectives: The aims of this study were to explore the clinical distribution, by species, of the genus Nocardia and to assess the antimicrobial susceptibilities of the 10 most prevalent species identified in Spain.
Introduction
Nocardia spp., which are actinomycetes with a wide environmental distribution, cause rare, opportunistic infections in humans, mainly in those who are immunodepressed, in those taking immunosuppressive drugs or corticosteroids, in those who have diabetes or neoplasms, in those who have undergone solid organ transplantation or in those who are alcohol abusers etc. However, they sometimes affect otherwise healthy persons. Nocardia spp. are responsible for a wide spectrum of clinical infections (both localized and disseminated) affecting the lungs, skin and CNS, the management of which is often hampered by delays in diagnosis. Widely disseminated infection, the presence of abscesses and granulomas, relapses and chronic infection can also make treatment a challenge. [1] [2] [3] [4] Moreover, the discovery of new Nocardia species, differences in the prevalence of Nocardia species between locations, variation in their susceptibility to antibiotics and differences in the results returned by different laboratories [5] [6] [7] [8] all hinder the selection of appropriate treatments.
Knowledge of the clinical impact of nocardiosis is generally scant and fragmentary. 3, 4 This remains true in Spain even though a number of studies have provided information on the epidemiology and clinical characteristics of nocardiosis in this country, as well as on the susceptibility to antibiotics of the bacteria involved. [9] [10] [11] [12] To further our knowledge of nocardiosis in Spain, the present work explores the epidemiology and susceptibility to antibiotics (using the Etest) of the 10 Nocardia species most commonly associated with human infection between 2005 and 2014. 
Materials and methods

Strains
Over the period 2005-14, 1119 Nocardia spp. strains were identified in clinical samples sent (from laboratories in 44 Spanish provinces) to the National Center for Microbiology (CNM, Majadahonda, Madrid, Spain) for microbial identification and antibiotic susceptibility testing. Strains were grown on Columbia agar supplemented with 5% (v/v) sheep blood and buffered charcoal-yeast extract agar (BCYE) for 48-72 h at 37 C under aerobic conditions. The strains were identified by the full sequencing of the 16S rRNA gene. This was complemented with the sequencing of other genes (secA1, hsp65 or gyrB) when necessary, [13] [14] [15] [16] [17] which was of particular importance for strains that were candidates for assignment to described Nocardia complexes. Using the BLAST algorithm, sequences were compared with those held in the NCBI database (http://www.ncbi.nlm.nih. gov). Species assignment was based on a similarity value of !99.6% for 16S, !99.0% for secA1 and !93.5% for gyrB.
3,13,17
Susceptibility to antibiotics
Susceptibilities to amoxicillin/clavulanate, cefotaxime, imipenem, amikacin, tobramycin, ciprofloxacin, erythromycin, minocycline, trimethoprim/sulfamethoxazole and linezolid were determined using the Etest (bioMérieux, Marcy-l' Etoile, France). For this, mature colonies of identified strains were removed using a sterile swab and transferred to 4.5 mL of sterile water. Five to seven 5 mm sterile glass beads were then added to each sample before repeated vortexing. Clumps were allowed to settle and the supernatant was adjusted to a turbidity equivalent to that of a 1.0 McFarland standard. 18 Samples were then plated onto 150 mm Mueller-Hinton blood agar plates and MICs determined after 48 h of incubation (72 h if required) at 37 C. 19 The MIC was defined as the value at which the inhibition zone intercepted the scale on the Etest strip. All MIC values were rounded up to the next highest dilution on the standard broth microdilution scale.
Resistance was recorded according to the CLSI criteria for broth microdilution; 18 intermediate values were categorized as resistant. The epidemiological cut-off was defined as two doubling dilutions above the MIC 50 or two doubling dilutions above the modal MIC. 8 The control strains used were Nocardia asteroides ATCC 19247 T , Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 35218.
Defining MDR
A tentative definition of MDR was established for the present work bearing in mind the previously described antimicrobial susceptibility profiles for Nocardia species. 2 Based on the CLSI list of antimicrobials for Nocardia and other aerobic actinomycetes, the antimicrobial categories proposed for the antibiotics tested in this work were: penicillins þ b-lactamase inhibitors (amoxicillin/clavulanic acid), third-and fourth-generation cephalosporins (cefotaxime), carbapenems (imipenem), aminoglycosides (amikacin, tobramycin), macrolides (erythromycin), tetracyclines (minocycline), fluoroquinolones (ciprofloxacin), folate pathway inhibitors (trimethoprim/sulfamethoxazole) and oxazolidinones (linezolid). Certain compounds in these categories could theoretically be substituted, such as cefotaxime by ceftriaxone or cefepime (in the cephalosporin category), minocycline by doxycycline (in the tetracycline category), ciprofloxacin by moxifloxacin (in the fluoroquinolone category) and erythromycin by clarithromycin (in the macrolide category). 20 The described acquired resistance profiles were: MDR (non-susceptibility to !1 agent in !3 antimicrobial categories); XDR (non-susceptibility to !1 agent in all but 2 categories); and pandrug resistance (PDR; non-susceptibility to all antibiotics); these are similar to the criteria of Magiorakos et al. 20 Finally, if a species showed intrinsic non-susceptibility to a specific antimicrobial, 2 this antimicrobial was not considered with respect to the designation of MDR status.
Statistical analysis
Categorical variables were compared using the v 2 test or two-tailed Fisher's exact test as required. Continuous variables were compared using Student's t-test (normally distributed variables) or the rank sum test (non-normally distributed variables). Significance was set at P 0.05. All calculations were performed using STATA v.13.1 software (StataCorp, College Station, TX, USA).
Results and discussion
Overview of human nocardiosis in Spain
A total of 1119 strains belonging to the genus Nocardia were identified. Between the two 5 year sub-periods of 2005-09 and 2010-14, the number of strains detected decreased by 25.1% from 640 to 479. Table S1 (available as Supplementary data at JAC Online) shows the four species most commonly detected over the entire 10 year period (together accounting for 64.4% of all the Nocardia species detected): Nocardia cyriacigeorgica (25.3%), Nocardia nova (15.0%), Nocardia abscessus (12.7%) and Nocardia farcinica (11. 4%). A long way behind, the next most common species were Nocardia carnea, Nocardia brasiliensis, Nocardia otitidiscaviarum, Nocardia flavorosea, Nocardia rhamnosiphila and Nocardia transvalensis (2.4%-4.3%). These 10 species accounted for 82.9% of the all strains encountered. The remaining 17.1% were represented by a further 32 Nocardia species plus Nocardia spp. (isolates identifiable only at the genus level). The distribution of the 10 main species was similar in both 5 year sub-periods, although N. abscessus, N. farcinica and N. transvalensis were significantly less common in the second sub-period (P 0.05), while the presence of the minor Nocardia species increased significantly from 14.1% to 21.1%.
The predominance of these species has been noted in previous Spanish studies, [9] [10] [11] although they appear in a different order, probably a consequence of the size of the sample and the period examined. A median 94 new cases/year were recorded in the present work, similar to the 92 new cases/year mentioned by Minero et al. 9 These species are also well represented in other countries, e.g. N. nova in Canada and the USA, 3,7 N. farcinica in Thailand and Japan 21, 22 and N. brasiliensis in Taiwan. 23 A total of 961 (85.9%) of the identified strains were isolated from respiratory tract samples, 101 (10.5%) from soft tissue and bone samples, 27 (2.8%) from CNS samples, 13 (1.3%) from blood samples and 17 (1.5%) from other samples (including five strains isolated from ocular samples and three from urinary tract samples). Table 1 shows the data recorded for each 5 year sub-period. No significant differences were seen between the two sub-periods with respect to the distribution of the sample types. Neither was any seen with respect to the distribution of the 10 most common species in the tested samples, except for N. farcinica, which showed a reduction in the number of strains in the second 5 year sub-period (from 91% to 37%; P 0.001). It should be noted, however, that over the 10 year period half of all strains isolated from the CNS belonged to N. farcinica, while $25% of those isolated from cutaneous samples belonged to N. farcinica or N. brasiliensis. This frequent association of N. farcinica with brain, skin and subcutaneous infections has recently been reported in a multicentre Overview and antibiotic resistance of the main Nocardia species in Spain JAC Table 1 . The taxonomic name N. rhamnosiphila is yet to be officially recognized.
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Valdezate et al.
study of solid organ transplant recipients. 24 N. flavorosea was only detected in respiratory samples.
Nocardial infections frequently call for prolonged therapy. Monotherapy with trimethoprim/sulfamethoxazole has evolved towards combined therapy with amikacin, which is effective against actinomycetoma and disseminated infections.
1,4 For strains not susceptible to trimethoprim/sulfamethoxazole, or when patients are immunosuppressed or have a severe infection, amikacin plus imipenem or b-lactams, or linezolid (for CNS infections or multiresistant strains), may be effective. 3, 12 Overall, low resistance rates (<10%) were seen with respect to linezolid, amikacin and imipenem, whereas intermediate rates (<25%) were recorded for trimethoprim/sulfamethoxazole, amoxicillin/clavulanic acid, cefotaxime and tobramycin, and high rates ($60%) were recorded for erythromycin, minocycline and ciprofloxacin (Table 2 ). In addition, lower MIC values (P 0.05) were observed for most of these agents during the second 5 year sub-period, the exceptions being for imipenem, trimethoprim/sulfamethoxazole and linezolid.
Susceptibility of the four most prevalent Nocardia species
Six major antimicrobial susceptibility patterns have traditionally been used to help identify Nocardia species.
1,2,4,8,25 Table 2 shows the MIC 50 , MIC 90 , epidemiological cut-off, resistance and MDR results for each of the 10 most prevalent species. Figure S1 shows the MIC distributions for the four most prevalent species: N. cyriacigeorgica, N. nova, N. abscessus and N. farcinica. The following sections discuss the results for the four most prevalent species (in decreasing order) at greater length.
N. cyriacigeorgica
The prevalence of the major aetiological agent of nocardiosis in Spain, N. cyriacigeorgica, remained stable over the two 5 year sub-periods (23.3% and 28.0%). Its involvement in clinical problems other than respiratory diseases was only $9.0% in both sub-periods. Its participation in soft tissue infections increased in the 2010-14 sub-period from 2.7% to 8.2% (Table  1 ). This species is associated with drug pattern type VI, characterized by resistance to ampicillin, amoxicillin/clavulanate (intermediate resistance), clarithromycin and ciprofloxacin, and by susceptibility to ceftriaxone, imipenem, amikacin and linezolid. 2 In agreement, the present results showed resistance rates of up to 70% for amoxicillin/clavulanate, erythromycin, minocycline and ciprofloxacin, and <5% for cefotaxime, imipenem, amikacin, tobramycin, trimethoprim/sulfamethoxazole and linezolid (Table 2) . However, 17 strains with 14 different profiles (6.0%) did not show a typical pattern VI, but instead showed resistance to cefotaxime and/or imipenem and/or amikacin and/or linezolid (Table S1 ). Resistance to imipenem has been previously reported. 26 During the second sub-period, a significant increase (P 0.05) in the MICs of amoxicillin/clavulanate, cefotaxime, amikacin and ciprofloxacin for N. cyriacigeorgica was detected, while the MIC of tobramycin fell significantly.
N. nova
The susceptibilities recorded for N. nova, which is associated with drug pattern III, only correspond to N. nova sensu stricto and not to other members of the N. nova complex (N. africana, N. elegans, Nocardia kruczakiae and Nocardia veterana). The major characteristics of drug pattern III are resistance to amoxicillin/clavulanate and susceptibility to ampicillin, ceftriaxone, imipenem, amikacin, erythromycin, clarithromycin and linezolid. 2 This species was very resistant to ciprofloxacin and minocycline (!90%) and resistant to amoxicillin/clavulanate and tobramycin (68% and 48%, respectively). Low resistance rates were recorded with respect to cefotaxime and trimethoprim/sulfamethoxazole (25% and 19.6%, respectively) and the species was susceptible to imipenem, amikacin, erythromycin and linezolid (<5%) ( Table 2 ). Forty-nine strains (29.2%) with 20 different phenotypes showed discrepancies with respect to the standard for drug pattern III, demonstrating resistance to cefotaxime and/or imipenem and/or amikacin and/or erythromycin and/or linezolid (Table S1 ). The MICs recorded for N. nova were similar for both sub-periods, except for amikacin, which returned a significantly lower value in the second sub-period.
N. abscessus
This species adhered to drug pattern I, i.e. resistance to ciprofloxacin and clarithromycin with frequent resistance to imipenem, but susceptibility to the remaining agents. 2 A ciprofloxacin resistance rate of 83.8% was recorded, 49.3% was recorded with respect to erythromycin and rates of 8.8% down to 0% were registered for the remaining agents (Table 2) . Ten strains showed eight phenotypes involving behaviour with respect to amoxicillin/clavulanate, cefotaxime, amikacin and linezolid that were different from the drug pattern I standard (Table S1 ). Significantly higher MICs were recorded for imipenem and amikacin, and significantly lower MICs were recorded for tobramycin, erythromycin and minocycline in the second sub-period.
N. farcinica
This species showed drug pattern V: resistance to ampicillin, broad-spectrum cephalosporins, clarithromycin and aminoglycosides (except amikacin) and susceptibility to imipenem, ciprofloxacin and linezolid. High resistance rates ($90%) were recorded for tobramycin, clarithromycin and minocycline, intermediate rates ($50%) with respect to cefotaxime, ciprofloxacin and trimethoprim/sulfamethoxazole, and low rates with respect to amoxicillin/clavulanate (18%), amikacin, imipenem and linezolid ( 3%). Sixty-six strains (51.6%) with 29 profiles differed with respect to the standard for drug pattern V in terms of their susceptibility to imipenem, amikacin, ciprofloxacin and linezolid (Table  S1 ). As recorded in other studies, 7 ,10 a large number of strains non-susceptible to trimethoprim/sulfamethoxazole (n ¼ 58) were recorded; the two modal MICs were 4 mg/L (n ¼ 18) and !32 mg/ L (n ¼ 28). In a previous study performed at our laboratory, 27 nearly all of the strains with high MICs (n ¼ 24) were screened for sul1-3 (dihydropteroate synthase) and a number of dfr (dihydrofolate reductase) genes. A major presence of sul1 and sul2 (n ¼ 22 strains) and a minor presence of dfrA1 (n ¼ 3 strains) were recorded. In the present work, significantly lower MICs of amikacin, tobramycin, erythromycin, minocycline and trimethoprim/ Overview and antibiotic resistance of the main Nocardia species in Spain JAC sulfamethoxazole for N. farcinica were recorded during the second sub-period. Table 2 shows the susceptibilities of the remaining six most prevalent species. Amoxicillin/clavulanate, resistance rates varied from close to 25% in N. carnea and N. rhamnosiphila to $60% in N. flavorosea and $90% in N. otitidiscaviarum. Lower resistance rates were recorded for these species with respect to cefotaxime, except for N. otitidiscaviarum, which returned a rate of 100%. Imipenem was less active against N. otitidiscaviarum, N. brasiliensis and N. transvalensis ($80%, $50% and $20%, respectively), but active (<3.5%) against the remaining three species. Amikacin and tobramycin were very active against all these species except for N. transvalensis, which returned resistance rates of close to 50% and 100%, respectively. Few strains belonging to these species were minocycline susceptible, with resistance rates running at some 60%-80%. Similar behaviour was seen with respect to erythromycin, with N. flavorosea the most susceptible. Only for N. brasiliensis and N. otitidiscaviarum were high rates of resistance to ciprofloxacin recorded ($60% and 40%, respectively). With respect to trimethoprim/sulfamethoxazole (the first choice in nocardiosis treatment) the highest resistance rates were recorded for N. carnea, N. flavorosea and N. transvalensis ($30%-40%). Finally, all the strains of these species were fully susceptible to linezolid.
Susceptibilities of the six next most prevalent Nocardia species
Comparison of resistance rates with those reported in other studies
The resistance rates obtained in the present study using the Etest method were compared with those recorded by other authors examining similar numbers of strains (except for N. brasiliensis and N. transvalensis), 8, 10 but employing the broth microdilution method (McFarland ODI 0.5, incubation !72 h). Identical or similar values were observed for most of the tested agents. However, several differences were also recorded (Table S2) . Variation in MIC results has also been recorded between and within laboratories when using the broth microdilution method. 28 Other authors have reported similar results. 6, 7, 29 This might be explained by technical differences, such as inoculum size, the time of incubation and/or the cut-offs used. The main differences are observed in the resistance rates of imipenem and trimethoprim/sulfamethoxazole, both with striking discrepancies in terms of Nocardia species susceptibilities. The loss of activity of imipenem in microdilution wells during storage at À20 C, or after 48 h of incubation at 37 C, 30 together with the difficulty in reading sulphonamide results in the broth microdilution method, 18 might account for these differences.
MDR
For the studied species with an assigned type of drug pattern, 2 the MDR values obtained for acquired resistance varied from $1% in N. cyriacigeorgica and N. abscessus to $10% in N. brasiliensis, $20% in N. transvalensis, $35% N. farcinica and N. otitidiscaviarum and $60% in N. nova (Table 2) . For species without a corresponding susceptibility pattern, the values ranged from 20% in N. rhamnosiphila to $40% in N. carnea and N. flavorosea. No strain had the XDR and PDR phenotype.
The level of intrinsic and acquired resistance varied from 20% in N. abscessus and N. rhamnosiphila to $40% in N. carnea and N. flavorosea, $60% in N. brasiliensis and N. transvalensis, $80% in N. nova and N. cyriacigeorgica, and 100% in N. otitidiscaviarum.
If the treatment of nocardiosis is to be improved, the species involved in an infection must be known; this would better guide treatment choices. However, some strains do not show the drug type pattern that normally corresponds to their species 31 (Table  S1 ). The present results show that some antibiotics can be ruled out for use against some species. For instance, amoxicillin/clavulanate, cefotaxime and imipenem would be ineffective against N. otitidiscaviarum, as would tobramycin against N. farcinica and N. transvalensis and ciprofloxacin against N. cyriacigeorgica, N. nova and N. abscessus. Erythromycin and minocycline, however, would be very effective against N. nova and N. abscessus, respectively. This study also confirms linezolid and amikacin to be the most effective agents against the 10 most prevalent Nocardia species in Spain and that N. farcinica, N. flavorosea and N. transvalensis show resistance rates of about 40% each to trimethoprim/sulfamethoxazole (the habitual therapeutic choice). The results confirm the need to properly identify the infecting species and its susceptibility to different antimicrobial agents if treatment is to be successful.
